GlassScriptPhysician profile
Vincent Brennan
NPI 1477110724
$724.49
in general payments reported to CMS, 2019-2025
19 companies · $690 in 2025
The $690 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.79 · 2021: $15.82 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $151.19 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $106.45 | 2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.44 | 2025 | Xifaxan |
| Pfizer INC. | $38.03 | 2025 | |
| Alk-Abello, INC | $37.94 | 2025 | Neffy, Ragwitek, Grastek |
| Abbvie INC. | $36.13 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.44 | 2025 | Jardiance |
| Lilly USA, LLC | $33.11 | 2025 | Kisunla, Mounjaro |
| Insmed, INC. | $30.82 | 2025 | Brinsupri, Arikayce |
| Amgen INC. | $30.00 | 2025 | Repatha, Evenity |
| Merck Sharp & Dohme LLC | $22.24 | 2025 | Capvaxive, Gardasil 9 |
| Tris Pharma INC | $18.79 | 2020 | |
| Electromed, INC. | $17.75 | 2025 | Smartvest |
| Tonix Medicines, INC. | $16.67 | 2025 | Tonmya |
| Glaxosmithkline, LLC. | $16.38 | 2025 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.29 | 2025 | Auvelity |
| Intercept Pharmaceuticals, INC. | $15.82 | 2021 | |
| Exact Sciences Corporation | $15.57 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $15.43 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.